Molecular pharmacodynamics of new oral drugs used in the treatment of multiple sclerosis

Drug Design, Development and Therapy

Volumn 8, Issue , 2014, Pages 555-567

  di Nuzzo, Luigi ^a   Orlando, Rosamaria ^b   Nasca, Carla ^a   Nicoletti, Ferdinando ^a,c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b OASI RESEARCH INSTITUTE IRCCS   (Italy)

^c IRCCS NEUROMED   (Italy)

Author keywords

Demyelinating diseases; Dimethyl fumarate; Fingolimod; Laquinimod; Pharmacotherapy; Teriflunomide

Indexed keywords

BETA INTERFERON; BRAIN DERIVED NEUROTROPHIC FACTOR; ERYTHROID DERIVED 2 RELATED FACTOR; FINGOLIMOD; FUMADERM; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; GLUTATHIONE; KYNURENINE; LAQUINIMOD; NUCLEAR FACTOR; PYRIMIDINE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; TERIFLUNOMIDE; TRYPTOPHAN; UNCLASSIFIED DRUG; CROTONIC ACID DERIVATIVE; FUMARIC ACID DERIVATIVE; NFE2L2 PROTEIN, HUMAN; PROPANEDIOL DERIVATIVE; QUINOLONE DERIVATIVE; SPHINGOSINE; TOLUIDINE DERIVATIVE; TRANSCRIPTION FACTOR NRF2;

AMINO ACID METABOLISM; BIOSYNTHESIS; BLOOD BRAIN BARRIER; CELL PROTECTION; CENTRAL NERVOUS SYSTEM; DISEASE COURSE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; IMMUNOREGULATION; MEMBRANE PERMEABILITY; METABOLIC REGULATION; MULTIPLE SCLEROSIS; NERVE CELL; PHARMACODYNAMICS; RECURRENCE RISK; REVIEW; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECTS; IMMUNE SYSTEM; ORAL DRUG ADMINISTRATION; PHYSIOLOGY;

ADMINISTRATION, ORAL; ANIMALS; BLOOD-BRAIN BARRIER; CROTONATES; FUMARATES; HUMANS; IMMUNE SYSTEM; MULTIPLE SCLEROSIS; NF-E2-RELATED FACTOR 2; PROPYLENE GLYCOLS; QUINOLONES; SPHINGOSINE; TOLUIDINES;

EID: 84901194938     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S52428     Document Type: Review

References (117)

1. Aktas O, Küry P, Kieseier B, Hartung HP. Fingolimod is a potential novel therapy for multiple sclerosis. Nat Rev Neurol. 2010;6(7):373-382.
2. Cohen JA, Barkhof F, Comi G, etal; TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402-415.
3. Kappos L, Radue EW, O'Connor P, etal; FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387-401.
4. Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol. 2010;33(2):91-101.
5. Boujaoude LC, Bradshaw-Wilder C, Mao C, etal. Cystic fibrosis transmembrane regulator regulates uptake of sphingoid base phosphates and lysophosphatidic acid: modulation of cellular activity of sphingosine 1-phosphate. J Biol Chem. 2001;276(38):35258-35264.
6. Kobayashi N, Nishi T, Hirata T, etal. Sphingosine 1-phosphate is released from the cytosol of rat platelets in a carrier-mediated manner. J Lipid Res. 2006;47(3):614-621.
7. Mitra P, Oskeritzian CA, Payne SG, Beaven MA, Milstien S, Spiegel S. Role of ABCC1 in export of sphingosine-1-phosphate from mast cells. Proc Natl Acad Sci U S A. 2006;103(44):16394-16399.
8. Rivera J, Proia RL, Olivera A. The alliance of sphingosine-1-phosphate and its receptors in immunity. Nat Rev Immunol. 2008;8(10): 753-763.
9. David OJ, Kovarik JM, Schmouder RL. Clinical pharmacokinetics of fingolimod. Clin Pharmacokinet. 2012;51(1):15-28.
10. Arnon TI, Xu Y, Lo C, etal. GRK2-dependent S1PR1 desensitization is required for lymphocytes to overcome their attraction to blood. Science. 2011;333(6051):1898-1903.
11. Mrowietz U, Asadullah K. Dimethylfumarate for psoriasis: more than a dietary curiosity. Trends Mol Med. 2005;11(1):43-48.
12. Rostami-Yazdi M, Mrowietz U. Fumaric acid esters. Clin Dermatol. 2008;26(5):522-526.
13. Gold R, Kappos L, Arnold DL, etal; DEFINE Study Investigators. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367(12):1098-1107. Erratum in: N Engl J Med. 2012;367(24):2362.
14. Fox RJ, Miller DH, Phillips JT, etal; CONFIRM Study Investigators. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367(12):1087-1097. Erratum in: N Engl J Med. 2012;367(17):1673.
15. Scannevin RH, Chollate S, Jung MY, etal. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J Pharmacol Exp Ther. 2012;341(1):274-284.
16. Ashrafian H, Czibik G, Bellahcene M, etal. Fumarate is cardioprotective via activation of the Nrf2 antioxidant pathway. Cell Metab. 2012;15(3):361-371.
17. Itoh K, Chiba T, Takahashi S, etal. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun. 1997;236(2):313-322.
18. Venugopal R, Jaiswal AK. Nrf2 and Nrf1 in association with Jun proteins regulate antioxidant response element-mediated expression and coordinated induction of genes encoding detoxifying enzymes. Oncogene. 1998;17(24):3145-3156.
19. Lin SX, Lisi L, Dello Russo C, etal. The anti-inflammatory effects of dimethyl fumarate in astrocytes involve glutathione and haem oxygenase-1. ASN Neuro. 2011;3(2):75-84.
20. Wakabayashi N, Slocum SL, Skoko JJ, Shin S, Kensler TW. When NRF2 talks, who's listening? Antioxid Redox Signal. 2010;13(11):1649-1663.
21. Brigelius-Flohé R, Flohé L. Basic principles and emerging concepts in the redox control of transcription factors. Antioxid Redox Signal. 2011;15(8):2335-2381.
22. Ji L, Li H, Gao P, etal. Nrf2pathway regulatesmultidrug-resistance-associated protein 1 in small cell lung cancer. PLoS One. 2013;8(5): e63404.
23. Kensler TW, Wakabayashi N. Nrf2: friend or foe for chemoprevention? Carcinogenesis. 2010;31(1):90-99.
24. Comi G, Jeffery D, Kappos L, etal; ALLEGRO Study Group. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med. 2012;366(11):1000-1009.
25. Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci. 2012;13(7):465-777.
26. Hönig A, Rieger L, Kapp M, Sütterlin M, Dietl J, Kämmerer U. Indoleamine 2,3-dioxygenase (IDO) expression in invasive extravillous trophoblast supports role of the enzyme for materno-fetal tolerance. J Reprod Immunol. 2004;61(2):79-86.
27. Fallarino F, Vacca C, Orabona C, etal. Functional expression of indoleamine 2,3-dioxygenase by murine CD8 alpha(+) dendritic cells. Int Immunol. 2002;14(1):65-68.
28. Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med. 2002;196(4):459-468.
29. Belladonna ML, Grohmann U, Guidetti P, etal. Kynurenine pathway enzymes in dendritic cells initiate tolerogenesis in the absence of functional IDO. J Immunol. 2006;177(1):130-137.
30. Chen Y, Meininger V, Guillemin GJ. Recent advances in the treatment of amyotrophic lateral sclerosis. Emphasis on kynurenine pathway inhibitors. Cent Nerv Syst Agents Med Chem. 2009;9(1):32-39.
31. Killestein J, Rudick RA, Polman CH. Oral treatment for multiple sclerosis. Lancet Neurol. 2011;10(11):1026-1034.
32. O'Connor P, Wolinsky JS, Confavreux C, etal; TEMSO Trial Group. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365(14):1293-1303.
33. Greene S, Watanabe K, Braatz-Trulson J, Lou L. Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide. Biochem Pharmacol. 1995;50(6):861-867.
34. Williamson RA, Yea CM, Robson PA, etal. Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound. J Biol Chem. 1995;270(38):22467-22472.
35. Fox RI, Herrmann ML, Frangou CG, etal. Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol. 1999;93(3):198-208.
36. Claussen MC, Korn T. Immune mechanisms of new therapeutic strategies in MS: teriflunomide. Clin Immunol. 2012;142(1):49-56.
37. Siemasko K, Chong AS, Jäck HM, Gong H, Williams JW, Finnegan A. Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production. J Immunol. 1998;160(4):1581-1588.
38. González-Alvaro I, Ortiz AM, Domínguez-Jiménez C, Aragón-Bodi A, Díaz Sánchez B, Sánchez-Madrid R. Inhibition of tumour necrosis factor and IL-17 production by leflunomide involves the JAK/STAT pathway. Ann Rheum Dis. 2009;68(10):1644-1650.
39. Mattar T, Kochhar K, Bartlett R, Bremer EG, Finnegan A. Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide. FEBS Lett. 1993;334(2):161-164.
40. Hamilton LC, Vojnovic I, Warner TD. A771726, the active metabolite of leflunomide, directly inhibits the activity of cyclo-oxygenase-2 in vitro and in vivo in a substrate-sensitive manner. Br J Pharmacol. 1999;127(7):1589-1596.
41. Cohen JA, Chun J. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. Ann Neurol. 2011;69(5):759-777.
42. Kivisäkk P, Mahad DJ, Callahan MK, etal. Expression of CCR7 in multiple sclerosis: implications for CNS immunity. Ann Neurol. 2004;55(5):627-638.
43. Brinkmann V, Billich A, Baumruker T, etal. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov. 2010;9(11):883-897.
44. Cyster JG, Schwab SR. Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs. Annu Rev Immunol. 2012;30:69-94.
45. Hla T, Brinkmann V. Sphingosine 1-phosphate (S1P): physiology and the effects of S1P receptor modulation. Neurology. 2011;76(8 Suppl 3): S3-S8.
46. Matloubian M, Lo CG, Cinamon G, etal. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature. 2004;427(6972):355-360.
47. Sallusto F, Mackay CR. Chemoattractants and their receptors in homeostasis and inflammation. Curr Opin Immunol. 2004;16(6):724-731.
48. Brinkmann V. FTY720 (fingolimod) in multiple sclerosis: therapeutic effects in the immune and the central nervous system. Br J Pharmacol. 2009;158(5):1173-1182.
49. Oo ML, Thangada S, Wu MT, etal. Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J Biol Chem. 2007;282(12):9082-9089.
50. Liu G, Burns S, Huang G, etal. The receptor S1P1 overrides regulatory T cell-mediated immune suppression through Akt-mTOR. Nat Immunol. 2009;10(7):769-777.
51. Liu G, Yang K, Burns S, Shrestha S, Chi H. The S1P(1)-mTOR axis directs the reciprocal differentiation of T(H)1 and T(reg) cells. Nat Immunol. 2010;11(11):1047-1056.
52. Sun Y, Wang W, Shan B, etal. FTY720-induced conversion of conventional Foxp3-CD4+ T cells to Foxp3+ regulatory T cells in NOD mice. Am J Reprod Immunol. 2011;66(5):349-362.
53. Daniel C, Sartory N, Zahn N, Geisslinger G, Radeke HH, Stein JM. FTY720 ameliorates Th1-mediated colitis in mice by directly affecting the functional activity of CD4+CD25+ regulatory T cells. J Immunol. 2007;178(4):2458-2468.
54. Kim HJ, Miron VE, Dukala D, etal. Neurobiological effects of sphingosine 1-phosphate receptor modulation in the cuprizone model. FASEB J. 2011;25(5):1509-1518.
55. Mehling M, Lindberg R, Raulf F, etal. Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis. Neurology. 2010;75(5):403-410.
56. Treumer F, Zhu K, Gläser R, Mrowietz U. Dimethyl fumarate is a potent inducer of apoptosis in human T cells. J Invest Dermatol. 2003;121(6): 1383-1388.
57. Mrowietz U, Asadullah K. Dimethyl fumarate for psoriasis: more than a dietary curiosity. Trends Mol Med. 2005;11(1):43-48.
58. Ormerod AD, Mrowietz U. Fumaric acid esters, their place in the treatment of psoriasis. Br J Dermatol. 2004;150(4):630-632.
59. Albrecht P, Bouchachia I, Goebels N, etal. Effects of dimethyl fumarate on neuroprotection and immunomodulation. J Neuroinflammation. 2012;9:163-172.
60. Peng H, Guerau-de-Arellano M, Mehta VB, etal. Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor κB (NF-κB) and extracellular signal-regulated kinase 1 and 2 (ERK1/2) and mitogen stress-activated kinase 1 (MSK1) signaling. J Biol Chem. 2012;287(33):28017-28026.
61. Ghoreschi K, Brück J, Kellerer C, etal. Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J Exp Med. 2011;208(11):2291-2303.
62. Brück W, Wegner C. Insight into the mechanism of laquinimod action. J Neurol Sci. 2011;306(1-2):173-179.
63. Toubi E, Nussbaum S, Staun-Ram E, etal. Laquinimod modulates B cells and their regulatory effects on T cells in multiple sclerosis. J Neuroimmunol. 2012;251(1-2):45-54.
64. Gurevich M, Gritzman T, Orbach R, Tuller T, Feldman A, Achiron A. Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: in-vitro high-throughput gene expression study. J Neuroimmunol. 2010;221(1-2):87-94.
65. Zou LP, Abbas N, Volkmann I, etal. Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue. Neuropharmacol. 2002;42(5):731-739.
66. Wegner C, Stadelmann C, Pförtner R, etal. Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis. J Neuroimmunol. 2010;227(1-2):133-143.
67. Aharoni R, Saada R, Eilam R, Hayardeny L, Sela M, Arnon R. Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis. J Neuroimmunol. 2012;251(1-2):14-24.
68. Schulze-Topphoff U, Shetty A, Varrin-Doyer M, etal. Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity. PLoS One. 2012;7(3):e33797.
69. Layseca-Espinosa E, Pedraza-Alva G, Montiel JL, etal. T cell aggregation induced through CD43: intracellular signals and inhibition by the immunomodulatory drug leflunomide. J Leukoc Biol. 2003;74(6):1083-1093.
70. Zeyda M, Poglitsch M, Geyeregger R, etal. Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formation. Arthritis Rheum. 2005;52(9):2730-2739.
71. Quéméneur L, Gerland LM, Flacher M, Ffrench M, Revillard JP, Genestier L. Differential control of cell cycle, proliferation, and survival of primary T lymphocytes by purine and pyrimidine nucleotides. J Immunol. 2003;170(10):4986-4995.
72. Dimitrova P, Skapenko A, Herrmann ML, Schleyerbach R, Kalden JR, Schulze-Koops H. Restriction of de novo pyrimidine biosynthesis inhibits Th1 cell activation and promotes Th2 cell differentiation. J Immunol. 2002;169(6):3392-3399.
73. Wang L, Chiang ET, Simmons JT, Garcia JG, Dudek SM. FTY720-induced human pulmonary endothelial barrier enhancement is mediated by c-Abl. Eur Respir J. 2011;38(1):78-88.
74. Sanchez T, Skoura A, Wu MT, Casserly B, Harrington EO, Hla T. Induction of vascular permeability by the sphingosine-1-phosphate receptor-2 (S1P2R) and its downstream effectors ROCK and PTEN. Arterioscler Thromb Vasc Biol. 2007;27(6):1312-1318.
75. Niessen F, Furlan-Freguia C, Fernández JA, etal. Endogenous EPCR/aPC-PAR1 signaling prevents inflammation-induced vascular leakage and lethality. Blood. 2009;113(12):2859-2866.
76. Balatoni B, Storch MK, Swoboda EM, etal. FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis. Brain Res Bull. 2007;74(5): 307-316.
77. Foster CA, Mechtcheriakova D, Storch MK, etal. FTY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood-brain-barrier damage. Brain Pathol. 2009;19(2):254-266.
78. Miron VE, Hall JA, Kennedy TE, Soliven B, Antel JP. Cyclical and dose-dependent responses of adult human mature oligodendrocytes to fingolimod. Am J Pathol. 2008;173(4):1143-1152.
79. van Doorn R, Nijland PG, Dekker N, etal. Fingolimod attenuates ceramide-induced blood-brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes. Acta Neuropathol. 2012;124(3):397-410.
80. Cannon RE, Peart JC, Hawkins BT, Campos CR, Miller DS. Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain. Proc Natl Acad Sci U S A. 2012;109(39):15930-15935.
81. Cartwright TA, Campos CR, Cannon RE, Miller DS. Mrp1 is essential for sphingolipid signaling to p-glycoprotein in mouse blood-brain and blood-spinal cord barriers. J Cereb Blood Flow Metab. 2013;33(3):381-388.
82. Jain N, Bhatti MT. Fingolimod-associated macular edema: incidence, detection, and management. Neurology. 2012;78(9):672-680.
83. Loewe R, Holnthoner W, Gröger M, etal. Dimethyl fumarate inhibits TNF-induced nuclear entry of NF-kappa B/p65 in human endothelial cells. J Immunol. 2002;168(9):4781-4787.
84. Meissner M, Doll M, Hrgovic I, etal. Suppression of VEGFR2 expression in human endothelial cells by dimethyl fumarate treatment: evidence for anti-angiogenic action. J Invest Dermatol. 2011;131(6): 1356-1364.
85. Soliven B, Miron V, Chun J. The neurobiology of sphingosine 1-phosphate signaling and sphingosine 1-phosphate receptor modulators. Neurology. 2011;76(8 Suppl 3):S9-S14.
86. Van Doorn R, Van Horssen J, Verzijl D, etal. Sphingosine 1-phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions. Glia. 2010;58(12):1465-1476.
87. Choi JW, Gardell SE, Herr DR, etal. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc Natl Acad Sci U S A. 2011;108(2):751-756.
88. Deogracias R, Yazdani M, Dekkers MP, etal. Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome. Proc Natl Acad Sci U S A. 2012;109(35):14230-14235.
89. Di Menna L, Molinaro G, Di Nuzzo L, etal. Fingolimod protects cultured cortical neurons against excitotoxic death. Pharmacol Res. 2013;67(1):1-9.
90. Czech B, Pfeilschifter W, Mazaheri-Omrani N, etal. The immunomodulatory sphingosine 1-phosphate analog FTY720 reduces lesion size and improves neurological outcome in a mouse model of cerebral ischemia. Biochem Biophys Res Commun. 2009;389(2):251-256.
91. Hasegawa Y, Suzuki H, Sozen T, Rolland W, Zhang JH. Activation of sphingosine 1-phosphate receptor-1 by FTY720 is neuroprotective after ischemic stroke in rats. Stroke. 2010;41(2):368-374.
92. Wei Y, Yemisci M, Kim HH, etal. Fingolimod provides long-term protection in rodent models of cerebral ischemia. Ann Neurol. 2011;69(1): 119-129.
93. Doi Y, Takeuchi H, Horiuchi H, etal. Fingolimodphosphate attenuates oligomeric amyloid β-induced neurotoxicity via increased brain-derived neurotrophic factor expression in neurons. PLoS One. 2013;8(4):e61988.
94. Molendijk ML, Bus BA, Spinhoven P, etal. A systematic review and meta-analysis on the association between BDNF val(66)met and hippocampal volume: a genuine effect or a winners curse? Am J Med Genet B Neuropsychiatr Genet. 2012;159B(6):731-740.
95. Kanellopoulos D, Gunning FM, Morimoto SS, etal. Hippocampal volumes and the brain-derived neurotrophic factor val66met polymorphism in geriatric major depression. Am J Geriatr Psychiatry. 2011;19(1):13-22.
96. Erickson KI, Prakash RS, Voss MW, etal. Brain-derived neurotrophic factor is associated with age-related decline in hippocampal volume. J Neurosci. 2010;30(15):5368-5375.
97. Benjamin S, McQuoid DR, Potter GG, etal. The brain-derived neurotrophic factor Val66Met polymorphism, hippocampal volume, and cognitive function in geriatric depression. Am J Geriatr Psychiatry. 2010;18(4):323-331.
98. Neto FL, Borges G, Torres-Sanchez S, Mico JA, Berrocoso E. Neurotrophins role in depression neurobiology: a review of basic and clinical evidence. Curr Neuropharmacol. 2011;9(4):530-552.
99. Wolkowitz OM, Wolf J, Shelly W, etal. Serum BDNF levels before treatment predict SSRI response in depression. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(7):1623-1630.
100. Yu H, Wang DD, Wang Y, Liu T, Lee FS, Chen ZY. Variant brain-derived neurotrophic factor Val66Met polymorphism alters vulnerability to stress and response to antidepressants. J Neurosci. 2012;32(12):4092-4101.
101. Coelho RP, Payne SG, Bittman R, Spiegel S, Sato-Bigbee C. The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors. J Pharmacol Exp Ther. 2007;323(2):626-635.
102. Jung CG, Kim HJ, Miron VE, etal. Functional consequences of S1P receptor modulation in rat oligodendroglial lineage cells. Glia. 2007;55(16):1656-1667.
103. Miron VE, Jung CG, Kim HJ, Kennedy TE, Soliven B, Antel JP. FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann Neurol. 2008;63(1):61-71.
104. Bieberich E. There is more to a lipid than just being a fat: sphingolipid-guided differentiation of oligodendroglial lineage from embryonic stem cells. Neurochem Res. 2011;36(9):1601-1611.
105. Hu Y, Lee X, Ji B, etal. Sphingosine 1-phosphate receptor modulator fingolimod (FTY720) does not promote remyelination in vivo. Mol Cell Neurosci. 2011;48(1):72-81.
106. Miron VE, Ludwin SK, Darlington PJ, etal. Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices. Am J Pathol. 2010;176(6):2682-2694.
107. Jackson SJ, Giovannoni G, Baker D. Fingolimod modulates microglial activation to augment markers of remyelination. J Neuroinflammation. 2011;8:76.
108. Kipp M, Amor S. FTY720 on the way from the base camp to the summit of the mountain: relevance for remyelination. Mult Scler. 2012;18(3):258-263.
109. Vladimirova O, O'Connor J, Cahill A, Alder H, Butunoi C, Kalman B. Oxidative damage to DNA in plaques of MS brains. Mult Scler. 1998;4(5):413-418.
110. Smith KJ, McDonald WI. The pathophysiology of multiple sclerosis: the mechanisms underlying the production of symptoms and the natural history of the disease. Philos Trans R Soc Lond B Biol Sci. 1999;354(1390):1649-1473.
111. Lee DH, Gold R, Linker RA. Mechanisms of oxidative damage in multiple sclerosis and neurodegenerative diseases: therapeutic modulation via fumaric acid esters. Int J Mol Sci. 2012;13(9):11783-11803.
112. Wilms H, Sievers J, Rickert U, Rostami-Yazdi M, Mrowietz U, Lucius R. Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1beta, TNF-alpha and IL-6 in an in-vitro model of brain inflammation. J Neuroinflammation. 2010;7:30.
113. Schmidt MM, Dringen R. Fumaric acid diesters deprive cultured primary astrocytes rapidly of glutathione. Neurochem Int. 2010;57(4): 460-467.
114. Thiessen A, Schmidt MM, Dringen R. Fumaric acid dialkyl esters deprive cultured rat oligodendroglial cells of glutathione and upregulate the expression of heme oxygenase 1. Neurosci Lett. 2010;475(1): 56-60.
115. Moharregh-Khiabani D, Blank A, Skripuletz T, etal. Effects of fumaric acids on cuprizone induced central nervous system de-and remyelination in the mouse. PLoS One. 2010;5(7):e11769.
116. Ruffini F, Rossi S, Bergamaschi A, etal. Laquinimod prevents inflammation-induced synaptic alterations occurring in experimental autoimmune encephalomyelitis. Mult Scler. 2012;19(8):1084-1094.
117. Raasch J, Zeller N, van Loo G, etal. IkappaB kinase 2 determines oligodendrocyte loss by non-cell-autonomous activation of NF-kappaB in the central nervous system. Brain. 2011;134(Pt 4):1184-1198.